@article{1d0856ced18b4a168e17141a3efe38df,
title = "Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier",
keywords = "B cell, BTK inhibitor, Clinical trial, Microglia, Multiple sclerosis",
author = "Greenberg, {Benjamin M.}",
note = "Funding Information: Dr B.M. Greenberg has received consulting fees from Alexion, Novartis, EMD Serono, Horizon Therapeutics, Genentech/Roche, Signant, IQVIA, Sandoz, Genzyme, Immunovant, TG Therapeutics, Cycle Pharma, PHAR, Intervenn, Arialys, Bayer, Janssen, Clene, Syneos, and PRIME Education. He has received grant funding from NIH, United States, Anokion, and Regeneron, United States. He serves as an unpaid member of the board of the Siegel Rare Neuroimmune Association. He has equity in Clene and GenrAb. He receives royalties from UpToDate. Funding Information: Dr B.M. Greenberg has received consulting fees from Alexion, Novartis, EMD Serono, Horizon Therapeutics, Genentech/Roche, Signant, IQVIA, Sandoz, Genzyme, Immunovant, TG Therapeutics, Cycle Pharma, PHAR, Intervenn, Arialys, Bayer, Janssen, Clene, Syneos, and PRIME Education. He has received grant funding from NIH, United States , Anokion , and Regeneron, United States . He serves as an unpaid member of the board of the Siegel Rare Neuroimmune Association. He has equity in Clene and GenrAb. He receives royalties from UpToDate.",
year = "2024",
month = feb,
doi = "10.1016/j.ncl.2023.07.006",
language = "English (US)",
volume = "42",
pages = "155--163",
journal = "Neurologic Clinics",
issn = "0733-8619",
publisher = "W.B. Saunders Ltd",
number = "1",
}